News
You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...
6d
The News-Herald on MSNBeth’s Place in Willoughby is owner’s ‘sanctuary’Being the owner of Beth’s Place in Willoughby does not feel like work for Elizabeth Mochu. Located at 37812 Vine St., Beth’s ...
8h
The Healthy @Reader's Digest on MSNSun Poisoning Symptoms to Watch Out ForToo much sun can do more than turn your skin red or brown—it can actually make you sick. About the experts Farah Moustafa, MD ...
16d
Flow Space on MSNHow to Make Sure Your Doctor Turns Your Symptoms Into an Accurate DiagnosisAs frustrating as that is, there are things you can do to make sure that your doctor turns your symptoms into an accurate diagnosis. Here's what to know. The first step to getting an accurate ...
Autoimmune diseases like lupus rheumatoid arthritis and psoriasis don’t just affect joints or skin they can silently damage the heart Learn how chronic inflammation raises cardiovascular risks ...
A new study found a high prevalence of chronic kidney disease (CKD) among people with systemic lupus erythematosus (SLE), ...
1d
MedPage Today on MSNYes, HCQ Does Help Preserve Renal Function in Lupus NephritisWhile hydroxychloroquine (HCQ) helps reduce disease flares in lupus, its effect on renal function in patients with lupus ...
Find out more about lupus: the symptoms, types, causes, and who is at risk for developing this chronic autoimmune disease.
In this video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, noted the ongoing efforts to define long COVID and recent data suggesting physicians are not treating ...
“Lupus can make navigating everyday life difficult. The skin manifestation, known as lupus rash, often comes with persistent itching, which can lead to scarring and hair loss.
Patient history commonly involves the use of topical corticosteroids. In some cases, patients may report a history of a mild facial rash medicated with moderately potent topical corticosteroids.
In its Phase II, double-blind, multicenter, randomized dose-ranging study, 142 subjects with moderate-to-severe plaque psoriasis were randomized to placebo or 10, 23, 75 or 150 mg of ixekizumab. [61] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results